Study endpoints
PD, tumor, SD
DISEASE, ADVERSE EVENT, TUMOR
Primary endpoints of the study were the DLT incidence rate, MTD, and RP2D. Secondary endpoints included other safety assessments, imaging tumor response (complete response [CR], PR, stable disease [SD], or progressive disease [PD]), and PK parameters of FCN-159. Adverse events were graded per CTCAE v5.0.